TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01938573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cystectomy when appropriate
Study: NCT01649609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate acid
Description: Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate acid
Description: Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
Study: NCT02899845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postural task

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walk task
Study: NCT01522807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
Study: NCT03248336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: office-based vergence/accommodative therapy
Description: one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
Study: NCT02482493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma PFC
Description: patients will receive either an all polyethylene tibial component or a metal- backed component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma PFC
Description: patients will receive either an all polyethylene tibial component or a metal- backed component
Study: NCT00967486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy with routine shount
Study: NCT01408797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: donor specific transfusion
Description: before transplantation,200mL of donor whole blood will be transfused to the recipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF, Bortezomib
Description: MMF and Bortezomib will be administered after donor specific transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drugs added according to the immuno condition of the recipients
Description: drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
Study: NCT00003387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02005939

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
Study: NCT01619956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLA dental implants
Description: Dental implant with surface modification.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLA dental implants
Description: Dental implant with surface modification.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation
Description: After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotome sinus floor elevation
Description: After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre.
Study: NCT04863092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
Study: NCT03157635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per schedule described in Part 1 placebo arm.
Study: NCT00967486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy with selective shunt
Study: NCT02811614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Evacuation
Description: Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Aspiration
Description: Using image guidance to aspirate hematoma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy
Description: Craniotomy with a big bone flap to evacuate intracerebral hematoma.
Study: NCT02759484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Enhanced Education
Description: The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Based Enhanced Education
Description: The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
Study: NCT02175784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral
Study: NCT03886662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.
Study: NCT02602392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lungtropolis
Description: A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma educational booklet
Description: Text-based asthma education booklet for parents and children in PDF format
Study: NCT02302534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI
Study: NCT02518204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPT
Description: Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPT
Description: Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP
Description: Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP
Description: Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV
Study: NCT00965809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
Study: NCT01922557

Intervention type: DEVICE
Intervention: NICOM
Description: NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
Study: NCT03159117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06688992
Description: (PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
Study: NCT05816031

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ketogenic diet
Description: Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy
Study: NCT04081324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01400815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-22 Smoking Cessation Product
Description: The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Cigarettes
Description: The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
Study: NCT01192373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic substrate modulation
Description: for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metabolic substrate modulation
Description: low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
Study: NCT04247776

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prehab
Description: Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: Enhanced Recovery After Surgery guidelines are applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Enhanced Recovery After Surgery guidelines are applied.
Study: NCT01619956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone grafting
Description: the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
Study: NCT04405908

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019
Description: SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019
Description: SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
Study: NCT04247776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit is worn to monitor step counts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit is worn to monitor step counts.
Study: NCT03181815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5mg/㎡ d1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300ug d0-9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclarubicin
Description: 10mg d3-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10mg/㎡ q12h SC d3-9
Study: NCT01948037

Intervention type: OTHER
Group type: OTHER
Intervention: hydrotherapy
Description: 30-minutes/per day,for 4weeks
Study: NCT00348153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study: NCT03915561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib Injectable Product
Description: Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
Study: NCT03969641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
Study: NCT03455036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: 10 x 1 min whole body vibration exposure
Study: NCT03293771

Intervention type: OTHER
Intervention: Focus group interviews
Description: Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire packet
Description: Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
Study: NCT03180255

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Description: Ocular iontophoretic delivery of a steroid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocular iontophoretic delivery of a placebo
Study: NCT02105909

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: GWAS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GWAS
Study: NCT01948037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: 30-minutes/per day,for 4weeks

Intervention type: OTHER
Group type: OTHER
Intervention: hydrotherapy
Description: 30-minutes/per day;4weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hydrotherapy
Description: 30-minutes/per day;4weeks
Study: NCT02575742

Intervention type: DEVICE
Intervention: 3D-Transit system

Intervention type: DEVICE
Intervention: 3D-Transit system

Intervention type: DEVICE
Intervention: 3D-Transit system

Intervention type: DEVICE
Intervention: 3D-Transit system
Study: NCT02664610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: hypertensive participants will be randomized to receive tailored, motivational text messages
Study: NCT02605785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV 1451
Description: Tau PET scan
Study: NCT04224389

Intervention type: PROCEDURE
Intervention: transoral resection
Description: The technique of transoral surgery will be left to the choice of the surgeon according to the equipment and the experience of the team and will be gathered. The options are: transoral surgery robot-assisted, endoscopic laser transoral surgery, transoral laser surgery classical instruments. The exact description of the resected area will be collected. of the cross-sections will be made for extemporaneous analysis if necessary in lateral margins and deep until complete excision.

Intervention type: RADIATION
Intervention: IMRT
Description: Intensity modulation radiotherapy (RCMI or IMRT) will be performed using techniques static or rotational (arctherapy, tomotherapy). Restraint is recommended with thermoformed mask
Study: NCT01352364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy intervention
Description: a program of physical therapy intervention can match or improve motor skills in the deaf children
Study: NCT02176278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Reminder
Description: Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Reminder
Description: Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doctor-Nurse Follow Up
Description: Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Risk Report for Patient Empowerment
Description: Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Risk Report for Patient Empowerment
Description: Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.